tysabri lawyer
The FDA has updated its warning on Biogen Idec’s many sclerosis drug Tysabri. According to the agency, the risk of a potentially fatal brain infection appears to be greatest in the course of the third year of remedy.
Given that Tysabri was reintroduced in 2006, Biogen and the FDA have been keeping close tabs on circumstances of progressive multifocal leukoencephalopathy, or PML. Biogen regularly updates case counts, and the FDA has been estimating the cumulative danger posed by the drug. This is the very first time the agency has calculated PML risk according to certain time intervals. The newly sliced information is designed to support doctors “greater assess threat based on duration of treatment,” the agency said. If you or an individual you know has suffered an injury due to Tysabri, they could be eligible for a Tysabri lawsuit.
PML threat amounts to .three instances per 1,000 throughout the initial two years of remedy, the agency mentioned. Soon after three years, the rate was .9 per 1,000. The highest risk was identified in patients treated with Tysabri for 25 to 36 months PML occurred in an estimated 1.5 per 1,000 patients during that time interval. The agency said it believes the positive aspects of utilizing Tysabri outweigh its risks.
Biogen spokeswoman Kate Weiss stated the FDA’s figures reinforced the company’s view that PML danger improved after two years of treatment, according to Reuters. The total quantity of circumstances worldwide came to 111 as of April 1, she mentioned.